We report results of the studies relating to fabrication of nanostructured metal oxide (NMO) based cancer biosensor. With the help of 2D electroactive reduced graphene oxide (RGO), we successfully inhibited the Brownian motion of NMO that led to reduced agglomeration of NMO. The nanostructured hafnium oxide (nHfO₂) was used as a model NMO. The reduced agglomeration of nHfO₂ was achieved through controlled hydrothermal synthesis and investigated via nanoparticles tracking analysis (NTA). X-ray diffraction (XRD), scanning electron microscopy (SEM) and transmission electron microscope (TEM) techniques were used for phase identification as well as morphological analysis of the synthesized nanohybrid (nHfO₂@RGO) material. The 3-aminopropyl triethoxysilane (APTES) was used for the functionalization of nHfO₂@RGO and electrophoretic deposition (EPD) technique was used for its deposition onto ITO coated glass electrode. Further, antibodies of cancer biomarker (anti-CYFRA-21-1) were immobilized via EDC-NHS chemistry and Bovine serum albumin (BSA) was used for blocking of the non-specific binding sites. The electrochemical response studies of fabricated immunoelectrode (BSA/anti-CYFRA-21-1/APTES/nHfO₂@RGO/ITO) revealed higher sensitivity (18.24 µA mL ng⁻¹), wide linear detection range (0 to 30 ng mL⁻¹), with remarkable lower detection limit (0.16 ng mL⁻¹). The obtained results showed good agreement with the concentration of CYFRA-21-1 obtained through enzyme linked immunosorbent assay (ELISA) in saliva samples of oral cancer patients.

我们报告有关基于纳米结构金属氧化物（NMO）的癌症生物传感器制造研究的结果。借助二维电活性还原氧化石墨烯（RGO），我们成功地抑制了NMO的布朗运动，从而降低了NMO的团聚。纳米结构的氧化ha（nHfO ₂）被用作NMO模型。通过控制水热合成可以减少nHfO _2的团聚，并可以通过纳米颗粒跟踪分析（NTA）进行研究。X射线衍射（XRD），扫描电子显微镜（SEM）和透射电子显微镜（TEM）技术用于合成纳米杂化物（nHfO ₂）的相识别和形态分析@RGO）材料。3-氨基丙基三乙氧基硅烷（APTES）用于nHfO ₂ @RGO的功能化，电泳沉积（EPD）技术用于其在ITO涂层玻璃电极上的沉积。此外，通过EDC-NHS化学方法固定了癌症生物标志物的抗体（抗CYFRA-21-1），并将牛血清白蛋白（BSA）用于封闭非特异性结合位点。制造的immunoelectrode的电化学反应研究（BSA /抗CYFRA-21-1 / APTES / nHfO ₂ @ RGO / ITO）显示更高的灵敏度（18.24毫升μA纳克^-1），宽的线性检测范围（0〜30毫微克毫升^{- 1}），具有极低的检测下限（0.16 ng mL ^-1）。所得结果与口腔癌患者唾液中通过酶联免疫吸附试验（ELISA）获得的CYFRA-21-1的浓度吻合良好。